| 000 | 01774 a2200493 4500 | ||
|---|---|---|---|
| 005 | 20250518023710.0 | ||
| 264 | 0 | _c20191230 | |
| 008 | 201912s 0 0 eng d | ||
| 022 | _a1874-1754 | ||
| 024 | 7 |
_a10.1016/j.ijcard.2018.12.078 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aKramer, Tilmann | |
| 245 | 0 | 0 |
_aTherapeutic potential of phosphodiesterase type 5 inhibitors in heart failure with preserved ejection fraction and combined post- and pre-capillary pulmonary hypertension. _h[electronic resource] |
| 260 |
_bInternational journal of cardiology _c05 2019 |
||
| 300 |
_a152-158 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aCardiac Catheterization |
| 650 | 0 | 4 | _aEchocardiography |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aFollow-Up Studies |
| 650 | 0 | 4 |
_aHeart Failure _xcomplications |
| 650 | 0 | 4 |
_aHeart Ventricles _xdiagnostic imaging |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aHypertension, Pulmonary _xdrug therapy |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aPhosphodiesterase 5 Inhibitors _xtherapeutic use |
| 650 | 0 | 4 | _aRetrospective Studies |
| 650 | 0 | 4 |
_aStroke Volume _xphysiology |
| 650 | 0 | 4 |
_aTadalafil _xtherapeutic use |
| 650 | 0 | 4 | _aTime Factors |
| 650 | 0 | 4 | _aTreatment Outcome |
| 650 | 0 | 4 |
_aVascular Resistance _xphysiology |
| 650 | 0 | 4 |
_aVentricular Function, Right _xphysiology |
| 700 | 1 | _aDumitrescu, Daniel | |
| 700 | 1 | _aGerhardt, Felix | |
| 700 | 1 | _aOrlova, Kristina | |
| 700 | 1 | _aTen Freyhaus, Henrik | |
| 700 | 1 | _aHellmich, Martin | |
| 700 | 1 | _aBaldus, Stephan | |
| 700 | 1 | _aRosenkranz, Stephan | |
| 773 | 0 |
_tInternational journal of cardiology _gvol. 283 _gp. 152-158 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/j.ijcard.2018.12.078 _zAvailable from publisher's website |
| 999 |
_c29385669 _d29385669 |
||